Literature DB >> 10468914

Prevalence of Ras mutations in thyroid neoplasia.

C T Esapa1, S J Johnson, P Kendall-Taylor, T W Lennard, P E Harris.   

Abstract

OBJECTIVE: Mutations at codons 12, 13 or 61 of ras which result in constitutive activation occur frequently in human malignancies. There have been varied reports on their prevalence and hence their likely significance in the pathogenesis of primary thyroid neoplasia. To address this, we have examined a large series of benign and malignant thyroid tumours for ras mutations.
DESIGN: Genomic DNA was analysed for the presence of mutations at codons 12, 13 and 61 of H-ras, K-ras and N-ras by allele-specific oligonucleotide hybridization. Direct DNA sequencing was used to confirm the mutations. PATIENTS: A total of 90 samples with benign (66) and malignant (24) thyroid disease were investigated.
RESULTS: A total of 14/90 (15.5%) samples had a ras mutation. All mutations were at codon 61 of either N-ras or K-ras. The positive cases were 1/25 (4%) nodular goitre, 7/38 (18%) follicular adenoma, 4/9 (44%) follicular carcinoma, 1/1 anaplastic carcinoma, 1/1 follicular variant of papillary carcinoma, and 1 metastatic follicular carcinoma in which the primary tumour had the same mutation.
CONCLUSIONS: Our data demonstrate a relatively low overall prevalence of ras mutations in thyroid neoplasia, with a predominance in follicular neoplasms. Their presence in follicular adenomas suggests that they may have an early aetiological role in the development of thyroid neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468914     DOI: 10.1046/j.1365-2265.1999.00704.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  44 in total

Review 1.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 2.  Molecular markers in well-differentiated thyroid cancer.

Authors:  Anil K D'Cruz; Richa Vaish; Abhishek Vaidya; Iain J Nixon; Michelle D Williams; Vincent Vander Poorten; Fernando López; Peter Angelos; Ashok R Shaha; Avi Khafif; Alena Skalova; Alessandra Rinaldo; Jennifer L Hunt; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-06       Impact factor: 2.503

Review 3.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

4.  Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.

Authors:  S H Jeong; H S Hong; J J Kwak; E H Lee
Journal:  J Endocrinol Invest       Date:  2015-05-22       Impact factor: 4.256

5.  Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Authors:  Tali Ofir Dovrat; Ethan Sokol; Garrett Frampton; Eliya Shachar; Sharon Pelles; Ravit Geva; Ido Wolf
Journal:  Cancer Biol Ther       Date:  2018-07-23       Impact factor: 4.742

Review 6.  The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Authors:  Levent Gürbüzler
Journal:  Turk Arch Otorhinolaryngol       Date:  2016-04-06

7.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

Review 8.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

9.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Authors:  Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

10.  Thyroid cancer: current molecular perspectives.

Authors:  Francesca Giusti; Alberto Falchetti; Francesco Franceschelli; Francesca Marini; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.